Mapp Biopharmaceutical Company Profile

03:50 EDT 22nd June 2018 | BioPortfolio

Mapp Biopharmaceutical was founded in 2003 to develop novel pharmaceuticals for the prevention and treatment of infectious diseases, focusing on unmet needs in global health and biodefense.

As Mapp's products transition to clinical evaluation, licenses are transferred to Mapp's commercialization partner, LeafBio.

ZMapp is composed of three “humanized” monoclonal antibodies manufactured in plants, specifically Nicotiana. It is an optimized cocktail combining the best components of MB--‐003 (Mapp) and ZMAb (Defyrus/PHAC).


6160 Lusk Blvd.Suite C105
San Diego
United States of America


Phone: 800 372 2176

News Articles [49 Associated News Articles listed on BioPortfolio]

Mapp Digital dévoile Mapp Cloud

Le lancement de Mapp Clouddémontre l'engagement de la société consistant à innover dans le domaine des services qu'exigent aujourd'hui les marketeurs numériques. Mapp Cloud Read more...

Mapp Digital Unveils Mapp Cloud

The introduction of Mapp Cloudshowcases the company's commitment to innovating the services digital marketers demand today. Mapp Cloudprovides marketers with a set of Read more...

Mapp Digital presenta Mapp Cloud

L'introduzione di Mapp Cloudmostra l'impegno dell'azienda verso l'innovazione dei servizi digitali richiesti dai professionisti del marketing. Mapp Cloudoffre ai professionisti del marketing una R...

Mapp Digital stellt Mapp Cloud vor

Die Einführung der Mapp Cloudzeigt, wie sehr sich das Unternehmen dafür einsetzt, die im Bereich des digitalen Marketings aktuell gestellten Anforderungen an innovative Dienstleistungen Read mor...

Promising treatment for Ebola to be tested at Texas Biomed

(Texas Biomedical Research Institute) During the West African Ebola outbreak that began in 2013, an experimental biopharmaceutical drug called ZMappTM was a glimmer of hope in the midst of a health cr...

FDA unveils draft guidance, MAPP on ANDA submissions

David SalazarThe Food and Drug Administration issued a draft guidance for generic manufacturers applying for approval, as well as a Manual of Policies and Procedures for FDA employees that codifies a ...

FDA Ends ANDA 'Reviews' To Streamline Approval Process

Instead, US agency will conduct 'assessments' of generic drug applications, according to new MaPP.   

In Switching Generic 'Reviews' To 'Assessments' Is US FDA Changing More Than Just A Word?

MaPP revision may be just a better description of ANDA evaluations – or indicative of a broad culture change, experts...    

Drugs and Medications [0 Results]


PubMed Articles [67 Associated PubMed Articles listed on BioPortfolio]

RAGE mediates Aβ accumulation in a mouse model of Alzheimer's disease via modulation of β- and γ-secretase activity.

Receptor for Advanced Glycation End products (RAGE) has been implicated in amyloid β-peptide (Aβ)-induced perturbation relevant to the pathogenesis of Alzheimer's disease (AD). However, whether and ...

Mutant APP and Amyloid beta-induced defective autophagy, mitophagy, mitochondrial structural and functional changes and synaptic damage in hippocampal neurons from Alzheimer's disease.

The purpose of our study was to determine the toxic effects of hippocampal mutant APP and amyloid beta (Aβ) in human mutant APP (mAPP) cDNA transfected with primary mouse hippocampal neurons (HT22). ...

Just how good an investment is the biopharmaceutical sector?

Uncertainty surrounding the risk and reward of investments in biopharmaceutical companies poses a challenge to those interested in funding such enterprises. Using data on publicly traded stocks, we tr...

Characterization of systems with amino-acids and oligosaccharides as modifiers of biopharmaceutical properties of furosemide.

Furosemide is the most commonly prescribed diuretic drug in spite of its suboptimal biopharmaceutical properties. In this work, the addition of different amino-acids was studied with the aim of select...

Biopharmaceutical Optimization in neglected diseases for paediatric patients by applying the provisional paediatric Biopharmaceutical Classification System.

Unavailability and lack of appropriate, effective and safe formulations are common problems in paediatric therapeutics. Key factors such as swallowing abilities, organoleptic preferences and dosage re...

Clinical Trials [9 Associated Clinical Trials listed on BioPortfolio]

Trans-MAPP Symptom Patterns Study (SPS)

This study is the second phase of the MAPP Network and is designed to conduct a prospective, observational study of men and women with UCPPS, referred to as the Symptom Patterns Study (SPS...

Trans-MAPP II Study of Urologic Chronic Pelvin Pain

The Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network has been established by the National Institute of Diabetes and Digestive and Kidney Diseases (NID...

Phase III Clinical Study of Efficacy and Safety of Vaccae™ to Prevent Tuberculosis

Mycobacterium Vaccae for Injection (Trade Name "Vaccae") is a kind of bio-products developed by Anhui Zhifei Longcom Biopharmaceutical Co.,Ltd.,and got "The New Drug Certificate "in 1999...

A Positron Emission Tomography (PET) Imaging Study to Investigate the Biodistribution and Clearance of an Albumin Binding Domain Antibody (AlbudAb) GSK3128349 in Healthy Male Subjects

GSK3128349 is a small protein molecule (biopharmaceutical) that binds to albumin in the body, and by itself, has no pharmacological action. A pharmacologically active drug can be attached ...

Juvista in the Non-surgical Improvement of Existing Scars

Renovo, a Biopharmaceutical company involved in the development of drugs to improve the appearance of scars and enhance wound healing, are proposing to carry out research in improving the ...

Companies [881 Associated Companies listed on BioPortfolio]

Mapp Biopharmaceutical

Mapp Biopharmaceutical was founded in 2003 to develop novel pharmaceuticals for the prevention and treatment of infectious diseases, focusing on unmet needs in global health and biodefense. As Mapp'...

Barrier Animal Healthcare

For far too long the control of Ragwort has been haphazard, unreliable and costly, that is until now. Barrier H is an innovation in Ragwort control, destroying this deadly weed in record time, right t...

Bavarian Nordic Research Institute A/S

Bavarian Nordic is a commercially viable international biopharmaceutical company through:Biopharmaceutical innovations Novel prophylactic and therapeutic approaches Development, production, testing an...

bde BioPharmaceutical Resources

bde BioPharmaceutical Resources is affiliated with a consortium of companies & consultants whose expertise can be utilized to perform a full spectrum of regulatory, scientific & manufacturing function...

Biopartners GmbH

BioPartners is an international biopharmaceutical company specialising in accelerating the global development and commercialisation of high quality recombinant biopharmaceutical products.

More Information about "Mapp Biopharmaceutical" on BioPortfolio

We have published hundreds of Mapp Biopharmaceutical news stories on BioPortfolio along with dozens of Mapp Biopharmaceutical Clinical Trials and PubMed Articles about Mapp Biopharmaceutical for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Mapp Biopharmaceutical Companies in our database. You can also find out about relevant Mapp Biopharmaceutical Drugs and Medications on this site too.

Quick Search


Relevant Topics

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...

Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Corporate Database Quicklinks

Searches Linking to this Company Record